Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Metsera Reports Phase 2b Results For First- And Best-In-Class Ultra-Long Acting GLP-1 RA Candidate MET-097i

Author: Benzinga Newsdesk | September 29, 2025 04:03pm

Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau

Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting

High study and treatment retention in both VESPER-1 and VESPER-3 trials

Data support Phase 3 initiation in late 2025

Posted In: MTSR